

***Fiscal Year 2016 Amyotrophic Lateral Sclerosis Research Program
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Therapeutic Development Award</p> <p>Go to: <u>Program Announcement</u> <u>General Application Instructions</u></p> <p>Grants.gov Funding Opportunity Number: <u>W81XWH-16-ALSRP-TDA</u></p>	<p>Independent investigators at all academic levels</p>	<ul style="list-style-type: none"> • Pre-application is required; full application submission is by invitation only. • Supports post-discovery, preclinical development of therapeutics for ALS • Preliminary data relevant to the phase of preclinical development are required • Types of efforts that will be supported include: <ul style="list-style-type: none"> ○ Development of pharmacological agents up to IND submission ○ Demonstration of target selectivity and mechanism of action, optimization of potency and pharmacology, studies of formulation, stability and production methods based on Good Manufacturing Practices ○ Development of biomarkers to confirm action on specific molecular targets or biomarkers of clinical progress • Collaboration with industry is encouraged • Clinical trials are not allowed • Does not support screening or development of screens or models 	<ul style="list-style-type: none"> • Maximum period of performance is 2 years. • Maximum funding of \$1,000,000 for direct costs • Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. 	<p>Pre-Application: April 14, 2016 5:00 p.m. Eastern Time (ET)</p> <p>Application: July 21, 2016 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Therapeutic Idea Award</p> <p>Go to: Program Announcement General Application Instructions</p> <p>Grants.gov Funding Opportunity Number: W81XWH-16-ALSRP-TIA</p>	<p>Independent investigators at all academic levels</p>	<ul style="list-style-type: none"> • Pre-application is required; full application submission is by invitation only. • Supports hypothesis-driven drug discovery efforts focused on ALS therapeutics • Preliminary data are not required • Types of efforts that will be supported include: <ul style="list-style-type: none"> ○ Novel exploitation of pathways known to be relevant to ALS for the purpose of improving treatment and/or advancing a novel treatment modality ○ Development, validation and use of novel of high-throughput screens and model systems based on novel targets or innovative drug systems ○ Development of methods for measuring engagement of mechanistic targets by drug candidates • Innovation in technologies and techniques is an important criteria • Characterization of mechanisms for the purpose of identifying new targets is outside of the scope of this announcement 	<ul style="list-style-type: none"> • The maximum period of performance is 2 years. • The maximum allowable funding for the entire period of performance is \$500,000 in direct costs. • Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. 	<p>Pre-Application : April 14, 2016 5:00 p.m. ET</p> <p>Application: July 21, 2016 11:59 p.m. ET</p>